We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Ruth M. O'Regan, MD

How to Improve Adjuvant Therapy in HER2-Positive Breast Cancer

  • Ruth M. O'Regan, MD
Jan 10, 2018

This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.

Genomic Subtypes in Choosing Adjuvant Therapy for Breast Cancer

  • Amelia B. Zelnak, MD, MSc
  • Ruth M. O'Regan, MD
Mar 15, 2013

Additional insight into the biology of ER-positive breast cancers, particularly the higher risk luminal B cancers, could aid in identifying potential targets and new, effective therapies. And though the majority of triple-negative breast cancers are the “basal-like” subtype, significant proportions are in other subtypes.

Adjuvant Anthracyclines: Time for a Change of Heart?

  • Ruth M. O'Regan, MD
Feb 19, 2011

As our knowledge of the molecular profiles of breast cancer has increased as a result of moving closer to our goal of individualized therapy, it is clear that we need to re-think our approach to the adjuvant treatment of early-stage breast cancer.

Long-Term Toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase Agents

  • Ruth M. O'Regan, MD
  • William J. Gradishar, MD
May 1, 2003

With the advent of aromatase
inhibitor use in the adjuvant
setting,[1] and the inception
of trials examining their use
for breast cancer prevention, it seems
prudent to evaluate what we know to
date about the long-term effects of these agents. Unfortunately, unlike selective
estrogen-receptor modulators
(SERMs)—in particular tamoxifen,[2]
which has been used for over 15 years
in patients with early-stage breast cancer-
long-term data on the use of aromatase
inhibitors are minimal.

Long-Term Toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase Agents

  • Ruth M. O'Regan, MD
  • William J. Gradishar, MD
May 1, 2003

With the advent of aromatase
inhibitor use in the adjuvant
setting,[1] and the inception
of trials examining their use
for breast cancer prevention, it seems
prudent to evaluate what we know to
date about the long-term effects of these agents. Unfortunately, unlike selective
estrogen-receptor modulators
(SERMs)—in particular tamoxifen,[2]
which has been used for over 15 years
in patients with early-stage breast cancer-
long-term data on the use of aromatase
inhibitors are minimal.

Commentary (Kaklamani/O’Regan): Aromatase Inhibitors as Adjuvant Therapy in Breast Cancer

  • Virginia G. Kaklamani, MD, DSc
  • Ruth M. O'Regan, MD
Mar 1, 2003

The use of aromatase inhibitors
has increased dramatically in
the past few years as a result
of the emergence of new, more specific
agents, such as anastrozole
(Arimidex), exemestane (Aromasin),
and letrozole (Femara). This class of
agents effectively blocks the peripheral
formation of estradiol, decreasing
its concentration to less than 10%,
while maintaining selectivity.[1]
Evaluation of these selective aromatase
inhibitors as adjuvant therapy
for early-stage breast cancer was
based on the findings of trials in
metastatic breast cancer, summarized
by Visvanathan and Davidson, that
demonstrated the equivalence and,
in some cases, superiority of the
aromatase inhibitors compared
with megestrol and tamoxifen,
including their superior side-effect
profile.[2-4]

Selective Estrogen-Receptor Modulators in 2001

  • Ruth M. O'Regan, MD
  • William J. Gradishar, MD
Sep 1, 2001

Tamoxifen (Nolvadex), a selective estrogen-receptor modulator, or SERM, is currently the endocrine therapy of choice for all stages of hormone-responsive breast cancer. Only tamoxifen has been approved by the US Food and

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.